Publication
Date | SPC No. | SPC
Category | Details
Rows may repeat to show multiple inventors or applicants depending on "Sort By" |
|---|
20 May 2015
(Journal 6574)
| SPC/GB03/033 | Extensions Lodged | Applicant: Shionogi Seiyaku Kabushiki Kaisha
1-8 Doshomachi 3-chome, Chuo-ku, Osaka 541, Japan
Product: Rosuvastatin optionally in the form of a non-toxic pharmaceutically acceptable salt, particularly the calcium salt.
Product Type: Medicinal
Authorised: NL 26872 6 November 2002
NL 26873 6 November 2002
NL 26874 6 November 2002
UK PL 17901/0201 21 March 2003
UK PL 17901/0202 21 March 2003
UK PL 17901/0203 21 March 2003
Authorised Extension: PL 17901/0201-0203 & 0243 30 October 2014
Patent No: EP0521471
Title: Pyrimidine Derivatives as HMG-CoA Reductase Inhibitors
SPC No: SPC/GB03/033
Date Lodged: 27 March 2015 |
20 May 2015
(Journal 6574)
| SPC/GB09/036 | Entered Into Force | Applicant: Pfizer Inc.
New York, NY 10017, USA
Product: Lasofoxifene, optionally in the form of a non toxic pharmacologically acceptable acid addition salt, N-oxide, ester or quaternary ammonium salt thereof, including the tartarate salt.
Product Type: Medicinal
Authorised: UK EU/1/08/500/001 24 February 2009
UK EU/1/08/500/002 24 February 2009
UK EU/1/08/500/003 24 February 2009
UK EU/1/08/500/004 24 February 2009
Authorised Extension:
Patent No: EP0802910
Title: Estrogen agonists/antagonists
SPC No: SPC/GB09/036
Date entered into force: 24 April 2015
Effective Period Expires On: 23 April 2020 |
20 May 2015
(Journal 6574)
| SPC/GB11/010 | Lapsed | Applicant: Boehringer Ingelheim Pharma GmbH & Co KG
Binger Strasse 173, D-55216 Ingleheim am Rhein, Germany
Product: The combination of a) Telmisartan, optionally in the form of pharmaceutically acceptable salts, and b) Amlodipine, optionally in the form of pharmaceutically acceptable salts, especially Amlodipine besylate
Product Type: Medicinal
Authorised: UK EU/1/10/648/001 7 October 2010
UK EU/1/10/648/002 7 October 2010
UK EU/1/10/648/003 7 October 2010
UK EU/1/10/648/004 7 October 2010
UK EU/1/10/648/005 7 October 2010
UK EU/1/10/648/006 7 October 2010
UK EU/1/10/648/007 7 October 2010
UK EU/1/10/648/008 7 October 2010
UK EU/1/10/648/009 7 October 2010
UK EU/1/10/648/010 7 October 2010
UK EU/1/10/648/011 7 October 2010
UK EU/1/10/648/012 7 October 2010
UK EU/1/10/648/013 7 October 2010
UK EU/1/10/648/014 7 October 2010
UK EU/1/10/648/015 7 October 2010
UK EU/1/10/648/016 7 October 2010
UK EU/1/10/648/017 7 October 2010
UK EU/1/10/648/018 7 October 2010
UK EU/1/10/648/019 7 October 2010
UK EU/1/10/648/020 7 October 2010
UK EU/1/10/648/021 7 October 2010
UK EU/1/10/648/022 7 October 2010
UK EU/1/10/648/023 7 October 2010
UK EU/1/10/648/024 7 October 2010
UK EU/1/10/648/025 7 October 2010
UK EU/1/10/648/026 7 October 2010
UK EU/1/10/648/027 7 October 2010
UK EU/1/10/648/028 7 October 2010
Authorised Extension:
Patent No: EP0502314
Title: Benzimidazol derivatives, medicaments containing them and process for their preparation
SPC No: SPC/GB11/010
Reason for Lapse: Surrendered
Date Lapsed: 22 April 2015 |
20 May 2015
(Journal 6574)
| SPC/GB15/024 | Lodged | Applicant: Bayer Intellectual Property GmbH
Alfred-Nobel-Strasse 10, 40789 Monheim, Germany
Product: Combination of imidacloprid and permethrin
Product Type: Medicinal
Authorised: IT ItalyA.I.C 103628018 13 August 2003
IT ItalyA.I.C 103628020 13 August 2003
IT ItalyA.I.C.103628032 13 August 2003
IT ItalyA.I.C 103628044 13 August 2003
IT ItalyA.I.C 103628057 13 August 2003
IT ItalyA.I.C 103626014 13 August 2003
IT ItalyA.I.C 103626026 13 August 2003
IT ItalyA.I.C 103626038 13 August 2003
IT ItalyA.I.C 103626040 13 August 2003
IT ItalyA.I.C 103628053 13 August 2003
UK Vm 00010/4136 23 December 2003
UK Vm 00010/4137 23 December 2003
UK Vm 00010/4138 23 December 2003
UK Vm 00010/4139 23 December 2003
Authorised Extension:
Patent No: EP1609362
Title: Non-systemic control of parasites
SPC No: SPC/GB15/024
Date Lodged: 22 April 2015 |
20 May 2015
(Journal 6574)
| SPC/GB15/025 | Lodged | Applicant: Bayer Intellectual Property GmbH
Alfred-Nobel-Strasse 10, 40789 Monheim, Germany
Product: Combination of imidacloprid and flumethrin
Product Type: Medicinal
Authorised: DE 401389.00.00 5 August 2011
UK Vm00010/4175 6 September 2011
Authorised Extension:
Patent No: EP1609362
Title: Non-systemic control of parasites
SPC No: SPC/GB15/025
Date Lodged: 22 April 2015 |
20 May 2015
(Journal 6574)
| | Expired | Sanofi-Aventis Deutschland GmbH
Brueningstrasse 50
65929 Frankfurt am Main
Germany
Product: Insulin Glargine (Lantus) optionally in the form of esters thereof or physiologically tolerated salts thereof.
Product Type: Medicinal
Authorised: United Kingdom EU/1/00/134/001 – 007 09/06/2000
Authorised Extension: EU/1/00/134/001 – 037 25/05/2012
Patent No: EP0368187
Title: Insulin derivatives, their use and a pharmaceutical composition containing same.
SPC Number: SPC/GB00/022
Extension Granted 12/03/2013
Extension Expired 05/05/2015 |
20 May 2015
(Journal 6574)
| | Expired | New York University
550 First Avenue, Rm. MSB 153, New York, NY
10016, USA
Janssen Biotech,Inc
800/850 Ridgeview Drive, Horsham, PA 19044, USA
Product: Chimeric human-murine monoclonal antibody
that binds with high affinity to both soluble and
transmembrane forms of TNF-α, but not lymphotoxin-α
(TNF-β), or a pharmaceutically acceptable salt or
derivative thereof, in particular an ester, ether, sulfate, c
Product Type: Medicinal
Authorised: UK EU/1/99/116/001-003 - 25 August 1999
Authorised Extension: EU/1/99/116/001-005 - 19 March
2012
Patent No: EP0610201
Title: Monoclonal and chimeric antibodies specific for
human tumor necrosis factor
SPC Number: SPC/GB01/049
Date Extension Granted: 12 March 2013 (See Journal No 6463 03/04/13)
Extension Expired On: 24 February 2015 (See journal no 6508 dated 12/2/14 re rectification) |
20 May 2015
(Journal 6574)
| | Expired | Novartis AG
Schwarzwaldallee 215, 4058 Basel, Switzerland
Product: Zoledronic acid optionally in the form of a salt
thereof
Product Type: Medicinal
Authorised: CH 55463 - 28 November 2000
UK EU/1/01/176/001 - 20 March 2001
UK EU/1/01/176/002 - 20 March 2001
UK EU/1/01/176/003 - 20 March 2001
Authorised Extension: C(2010)524 - 25 January 2010
Patent No: EP0275821
Title: Substituted alkanediphosphonic acids
SPC Number: SPC/GB01/039
Date Extension Granted: 30 June 2010 (See Journal No 6323 28/07/2010)
Extension Expired On: 15 May 2013 |
20 May 2015
(Journal 6574)
| | Expired | Merck Canada Inc.
16711 Trans-Canada Highway, Kirkland, Quebec,
H9H 3L1, Canada
Product: Montelukast, or a pharmaceutically acceptable
salt thereof, preferably montelukast sodium
Product Type: Medicinal
Authorised: FI 12766 - 25 August 1997
FI 12767 - 25 August 1997
UK 00025/0357 - 15 January 1998
UK 00025/0358 - 15 January 1998
Authorised Extension: PL00025/0412 & 0440 - 20
December 2010
Patent No: EP0480717
Title: Unsaturated hydroxyalkylquinoline acids as
leukotriene antagonists
SPC Number: SPC/GB98/025
Date Extension Granted: 3 January 2012 (See Journal No 6402 01/02/12)
Extension Expired On: 24 February 2013 |
20 May 2015
(Journal 6574)
| | Expired | Pfizer Health AB
Vetenskapsvagen 10, 191 90 Sollentuna, Sweden
Product: Latanoprost
(i.e.
13,14-dihydro-17-phenyl-18,19,20-trinor-PGF₂α-
isopropylester)
Product Type: Medicinal
Authorised: SE 12716 - 18 July 1996
UK 00032/0220 - 16 December 1996
Authorised Extension: PL00057/1057-008 - 16
December 2010
Patent No: EP0364417
Title: Prostaglandin derivatives for the treatment of
Glaucoma or Ocular Hypertension
SPC Number: SPC/GB97/014
Date Extension Granted: 10 May 2011 (See Journal No 6366 25/05/2011)
Extension Expired On: 17 January 2012 |
